SCHEMBL23217566

SCHEMBL23217566

CCOC(=O)Cc1ccccc1OCc1cc(-c2ccnc(CN)c2F)c2occ(F)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 13/20 0.45
TBXAS1 P24557 1/20 0.40
DPP4 P27487 2/20 0.38
PLG P00747 1/20 0.35
PLAU P00749 1/20 0.35
F11 P03951 1/20 0.35
KLKB1 P03952 1/20 0.35
F7 P08709 1/20 0.35
TPSB2 P20231 1/20 0.35
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PRMT5 O14744 1/20 0.34
TP53 P04637 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30010416 1.00 CFD (0.45) CFDTBXAS1DPP4PLGPLAU
SCHEMBL23217696 0.91 CFD (0.45) CFDTBXAS1DPP4PLGPLAU
SCHEMBL30009689 0.91 CFD (0.45) CFDTBXAS1DPP4PLGPLAU
SCHEMBL21438178 0.91 CFD (0.43) CFDTBXAS1DPP4PLGPLAU
SCHEMBL29672988 0.90 CFD (0.55) CFDPLGPLAUF11KLKB1
SCHEMBL23217266 0.90 CFD (0.55) CFDPLGPLAUF11KLKB1
SCHEMBL30010531 0.89 CFD (0.56) CFDTBXAS1DPP4PLGPLAU
SCHEMBL21438599 0.89 CFD (0.56) CFDTBXAS1DPP4PLGPLAU
SCHEMBL23217672 0.87 CFD (0.44) CFDTBXAS1DPP4PLGPLAU
SCHEMBL30010663 0.87 CFD (0.44) CFDTBXAS1DPP4PLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885TBXAS1 519/4885DPP4 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.